Ranbaxy & Orchid announce strategic business alliance

RELATED NEWS Ranbaxy to launch generic version of Nexium in 2014 Orchid Chemicals, Ranbaxy ink product pact Ranbaxy Q1 cons net up 19.91% Rs 153 cr ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 13/02/12 Are Mutual Funds betting on Ranbaxy Labs? Other Stocks in this news Orchid Chemicals and Pharmaceuticals |

Ranbaxy Laboratories Limited (Ranbaxy) and Orchid Chemicals & Pharmaceuticals Limited (Orchid) today announced that they have entered into a Business Alliance Agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients.  Additionally, this agreement would establish a framework for enhanced future co-operation between the two  companies.

 

Speaking on the development, Mr. Malvinder Mohan Singh, CEO & MD,  Ranbaxy, said, "Orchid is a niche player in the global pharmaceutical industry with an impressive track record, particularly in sterile products.  We are pleased to enter into this long term strategic  alliance with Orchid. The agreement will be mutually beneficial and synergistic, allowing both organisations to leverage each others inherent strengths." 

 

Commenting on the alliance, Mr. K. Raghavendra Rao, Managing Director, Orchid, said, "We are happy to join hands with Ranbaxy, India's largest pharmaceutical company. Ranbaxy's global scale and market reach and Orchid's state-of-the-art development and manufacturing capabilities would expand the business of both companies. We believe that this will be a win-win arrangement for both companies"

 

Sourced From: Ranbaxy Laboratories Ltd